Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus

Circulation: Cardiovascular Imaging

Volumn 6, Issue 2, 2013, Pages 295-301

  Puntmann, Valentina O ^a   D'Cruz, David ^a   Smith, Zachary ^a   Pastor, Ana ^a   Choong, Peng ^a   Voigt, Tobias ^b   Carr White, Gerry ^a   Sangle, Shirish ^a   Schaeffter, Tobias ^a   Nagel, Eike ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b PHILIPS RESEARCH LABORATORIES   (Netherlands)

Author keywords

Late gadolinium enhancement; Subclinical cardiomyopathy; T1 mapping; Tissue characterization

Indexed keywords

GADOLINIUM; CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOBUTROL; ORGANOMETALLIC COMPOUND;

ADULT; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE PERFUSION; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTOLE; ASYMPTOMATIC DISEASE; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL PERFUSION IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; STATISTICAL MODEL;

ADULT; ASYMPTOMATIC DISEASES; CARDIOMYOPATHIES; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CONTRAST MEDIA; FEMALE; HUMANS; LINEAR MODELS; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL PERFUSION IMAGING; MYOCARDIUM; ORGANOMETALLIC COMPOUNDS; PREDICTIVE VALUE OF TESTS; SYSTOLE; VENTRICULAR FUNCTION, LEFT;

MLCS; MLOWN;

EID: 84877252985     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.112.000151     Document Type: Article

References (45)

1. Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus. 2005;14:683-686.
2. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen- McWilliams L, D'Agostino RB, Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145:408-415.
3. Logar D, Kveder T, Rozman B, Dobovisek J. Possible association between anti-Ro antibodies and myocarditis or cardiac conduction defects in adults with systemic lupus erythematosus. Ann Rheum Dis. 1990;49:627-629.
4. Bidani AK, Roberts JL, Schwartz MM, Lewis EJ. Immunopathology of cardiac lesions in fatal systemic lupus erythematosus. Am J Med. 1980;69:849-858.
5. Crozier IG, Li E, Milne MJ, Nicholls MG. Cardiac involvement in systemic lupus erythematosus detected by echocardiography. Am J Cardiol. 1990;65:1145-1148.
6. Palmieri V, Migliaresi P, Orefice M, Lupo T, Di Minno MN, Valentini G, Celentano A. High prevalence of subclinical cardiovascular abnormalities in patients with systemic lupus erythematosus in spite of a very low clinical damage index. Nutr Metab Cardiovasc Dis. 2009;19:234-240.
7. Pieretti J, Roman MJ, Devereux RB, Lockshin MD, Crow MK, Paget SA, Schwartz JE, Sammaritano L, Levine DM, Salmon JE. Systemic lupus erythematosus predicts increased left ventricular mass. Circulation. 2007;116:419-426.
8. Abdel-Aty H, Siegle N, Natusch A, Gromnica-Ihle E, Wassmuth R, Dietz R, Schulz-Menger J. Myocardial tissue characterization in systemic lupus erythematosus: value of a comprehensive cardiovascular magnetic resonance approach. Lupus. 2008;17:561-567.
9. Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest J Jr. Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol. 1999;26:2363-2368.
10. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992;93:513-519.
11. Bruce IN. 'Not only.but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford). 2005;44:1492-1502.
12. Nikpour M, Gladman DD, Ibañez D, Bruce IN, Burns RJ, Urowitz MB. Myocardial perfusion imaging in assessing risk of coronary events in patients with systemic lupus erythematosus. J Rheumatol. 2009;36:288-294.
13. Sasson Z, Rasooly Y, Chow CW, Marshall S, Urowitz MB. Impairment of left ventricular diastolic function in systemic lupus erythematosus. Am J Cardiol. 1992;69:1629-1634.
14. Buss SJ, Wolf D, Korosoglou G, Max R, Weiss CS, Fischer C, Schellberg D, Zugck C, Kuecherer HF, Lorenz HM, Katus HA, Hardt SE, Hansen A. Myocardial left ventricular dysfunction in patients with systemic lupus erythematosus: new insights from tissue Doppler and strain imaging. J Rheumatol. 2010;37:79-86.
15. Mavrogeni S, Vassilopoulos D. Is there a place for cardiovascular magnetic resonance imaging in the evaluation of cardiovascular involvement in rheumatic diseases? Semin Arthritis Rheum. 2011;41:488-496.
16. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White JA, Abdel-Aty H, Gutberlet M, Prasad S, Aletras A, Laissy JP, Paterson I, Filipchuk NG, Kumar A, Pauschinger M, Liu P; International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 2009;53:1475-1487.
17. Been M, Thomson BJ, Smith MA, Ridgway JP, Douglas RH, Been M, Best JJ, Muir AL. Myocardial involvement in systemic lupus erythematosus detected by magnetic resonance imaging. Eur Heart J. 1988;9:1250-1256.
18. O'Neill SG, Woldman S, Bailliard F, Norman W, McEwan J, Isenberg DA, Taylor AM, Rahman A. Cardiac magnetic resonance imaging in patients with systemic lupus erythematosus. Ann Rheum Dis. 2009;68:1478-1481.
19. Puntmann VO, Taylor PC, Barr A, Schnackenburg B, Jahnke C, Paetsch I. Towards understanding the phenotypes of myocardial involvement in the presence of self-limiting and sustained systemic inflammation: a magnetic resonance imaging study. Rheumatology (Oxford). 2010;49:528-535.
20. Pastor A, Voigt T, Schaeffter, Nagel E, Puntmann VO. Usefulness of cardiac magnetic resonance in early assessment of cardiomyopathies: myocardial fibrosis is a common denominator. Cur CV imaging Rep. 2012;5:77-82.
21. Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP. Modified Look-Locker inversion recovery (MOLLI) for highresolution T1 mapping of the heart. Magn Reson Med. 2004;52:141-146.
22. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, McGregor C, Moon JC. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010;122:138-144.
23. Jellis C, Wright J, Kennedy D, Sacre J, Jenkins C, Haluska B, Martin J, Fenwick J, Marwick TH. Association of imaging markers of myocardial fibrosis with metabolic and functional disturbances in early diabetic cardiomyopathy. Circ Cardiovasc Imaging. 2011;4:693-702.
24. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, Kaye DM, Taylor AJ. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008;52:1574-1580.
25. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
26. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363-369.
27. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35: 630-640.
28. Yee CS, Farewell VT, Isenberg DA, Griffiths B, Teh LS, Bruce IN, Ahmad Y, Rahman A, Prabu A, Akil M, McHugh N, Edwards C, D'Cruz D, Khamashta MA, Gordon C. The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford). 2011;50: 982-988.
29. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E; Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on Standardized Protocols. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. J Cardiovasc Magn Reson. 2008;10:35.
30. Plein S, Ryf S, Schwitter J, Radjenovic A, Boesiger P, Kozerke S. Dynamic contrast-enhanced myocardial perfusion MRI accelerated with k-t sense. Magn Reson Med. 2007;58:777-785.
31. Morton G, Ishida M, Schuster A, Hussain S, Schaeffter T, Chiribiri A, Nagel E. Perfusion cardiovascular magnetic resonance: comparison of an advanced, high-resolution and a standard sequence. J Cardiovasc Magn Reson. 2012;14:34.
32. Piechnik SK, Ferreira VM, Dall'Armellina E, Cochlin LE, Greiser A, Neubauer S, Robson MD. Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson. 2010;12:69.
33. Hor KN, Gottliebson WM, Carson C, Wash E, Cnota J, Fleck R, Wansapura J, Klimeczek P, Al-Khalidi HR, Chung ES, Benson DW, Mazur W. Comparison of magnetic resonance feature tracking for strain calculation with harmonic phase imaging analysis. JACC Cardiovasc Imaging. 2010;3:144-151.
34. Puntmann VO, Nagel E, Hughes AD, Gebker R, Gaddum N, Chowienczyk P, Jahnke C, Mirelis J, Schnackenburg B, Paetsch I, Fleck E. Genderspecific differences in myocardial deformation and aortic stiffness at rest and dobutamine stress. Hypertension. 2012;59:712-718.
35. Grün S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, Kispert EM, Hill S, Ong P, Klingel K, Kandolf R, Sechtem U, Mahrholdt H. Longterm follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol. 2012;59:1604-1615.
36. Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, Sheppard MN, Poole-Wilson PA, Pennell DJ. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1977-1985.
37. Karadag O, Calguneri M, Yavuz B, Atalar E, Akdogan A, Kalyoncu U, Kiraz S, Aksoyek S, Ozmen F, Ertenli AI. B-type natriuretic peptide (BNP) levels in female systemic lupus erythematosus patients: what is the clinical significance? Clin Rheumatol. 2007;26:1701-1704.
38. Chung CP, Solus JF, Oeser A, Avalos I, Kurnik D, Raggi P, Stein CM. N-terminal pro-brain natriuretic peptide in systemic lupus erythematosus: relationship with inflammation, augmentation index, and coronary calcification. J Rheumatol. 2008;35:1314-1319.
39. Nadir MA, Rekhraj S, Wei L, Lim TK, Davidson J, MacDonald TM, Lang CC, Dow E, Struthers AD. Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease. J Am Coll Cardiol. 2012;60:960-968.
40. Nielsen OW, McDonagh TA, Robb SD, Dargie HJ. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol. 2003;41:113-120.
41. Bottomley PA, Foster TH, Argersinger RE, Pfeifer LM. A review of normal tissue hydrogen NMR relaxation times and relaxation mechanisms from 1-100 MHz: dependence on tissue type, NMR frequency, temperature, species, excision, and age. Med Phys. 1984;11:425-448.
42. Cameron IL, Ord VA, Fullerton GD. Characterization of proton NMR relaxation times in normal and pathological tissues by correlation with other tissue parameters. Magn Reson Imaging. 1984;2:97-106.
43. Scholz TD, Fleagle SR, Burns TL, Skorton DJ. Nuclear magnetic resonance relaxometry of the normal heart: relationship between collagen content and relaxation times of the four chambers. Magn Reson Imaging. 1989;7:643-648.
44. Messroghli DR, Walters K, Plein S, Sparrow P, Friedrich MG, Ridgway JP, Sivananthan MU. Myocardial T1 mapping: application to patients with acute and chronic myocardial infarction. J Magn Reson Imaging. 2007;26:1081-6.
45. Ugander M, Oki AJ, Hsu LY, Kellman P, Greiser A, Aletras AH, Sibley CT, Chen MY, Bandettini WP, Arai AE. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J. 2012;33:1268-1278.